Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.60 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5812547 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 | |
| SCHEMBL8856372 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 | |
| SCHEMBL5811648 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 | |
| SCHEMBL1683844 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 | |
| SCHEMBL19385432 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 | |
| SCHEMBL3241254 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 | |
| SCHEMBL3182155 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 | |
| SCHEMBL9097995 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 | |
| SCHEMBL2499651 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 | |
| SCHEMBL7521220 | 0.98 | ZDHHC7 (0.63) | ZDHHC7GPR84FFAR1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| WO-2025132660-A1 | METHOD FOR TREATING HUMAN PERSPIRATION, AND ASSOCIATED COMPOSITION | L'OREAL (FR) | 2025-06-26 | — | — | WO | disclosed |
| US-20250009621-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER | L'OREAL (FR) | 2025-01-09 | — | — | US | disclosed |
| WO-2025006991-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER | L'OREAL (FR) | 2025-01-02 | — | — | WO | disclosed |
| WO-2022228652-A1 | MEANS AND METHOD FOR TREATING VIRAL INFECTIONS | BIRKENMEIER GERD (DE) | 2022-11-03 | — | — | WO | disclosed |
| CN-112062747-A | Preparation method of caprolactone | 青岛科技大学 | 2020-12-11 | — | — | CN | disclosed |
| CN-106795537-A | Methods, reagents and cells for biosynthesis of compounds | 英威达技术有限责任公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-1874407-B1 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GMB (DE) | 2015-09-09 | — | — | EP | disclosed |
| EP-1877141-B1 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | BIOMAC PRIVATINSTITUT FUER MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG ENTWICKLUNG UND DIAGNOSTIK GM (DE) | 2013-06-12 | — | — | EP | disclosed |
| CN-101802159-B | Anti-microbial composition | BYOTROL PLC | 2013-03-27 | — | — | CN | disclosed |
| WO-2006108682-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AS ANTI-FUNGAL AGENTS | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108681-A2 | SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS FOR THE INHIBITION OF GLYOXALASES AND THEIR USE AGAINST BACTERIA | BIOMAC PRIVATINSTITUT FÜR MEDIZINISCHE UND ZAHNMEDIZINISCHE FORSCHUNG, ENTWICKLUNG UND DIAGNOSTIK GMBH (DE) | 2006-10-19 | — | — | WO | disclosed |
| EP-1458382-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2003-09-11 | — | — | US | disclosed |
| EP-1336607-A1 | Amide derivatives as glucokinase activators | NOVO NORDISK A/S (DK) | 2003-08-20 | — | — | EP | disclosed |
| WO-2003055482-A1 | AMIDE DERIVATIVES AS GK ACTIVATORS | NOVO NORDISK A/S (DK) | 2003-07-10 | — | — | WO | disclosed |
| US-5374638-A | Cardiovascular disorders, hypotensive agents | MERCK & CO., INC. (US) | 1994-12-20 | — | — | US | disclosed |
| WO-1994021255-A1 | SIX-MEMBERED RING FUSED IMIDAZOLES SUBSTITUTED WITH PHENOXYPHENYLACETIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 1994-09-29 | — | — | WO | disclosed |
| US-5334598-A | Have endothelin antagonist activity; useful in treating cardiovascular disorders, hypertension, inflammatory diseases and asthma | MERCK & CO., INC. (US) | 1994-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250009621-A1 | ANHYDROUS HAIR TREATMENT COMPOSITION COMPRISING ALPHA HYDROXY ACID ESTER | EBP, ADH1A, ADH1C | ZDHHC7 1572/4885GPR84 205/4885FFAR1 234/4885 |
| US-20030171411-A1 | Amide derivatives as therapeutic agents | GK, GCKR, GCK | ZDHHC7 496/4885GPR84 588/4885FFAR1 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.